Angelica Welch

Robert Dean, MD, discusses the promise for new therapies in mantle cell lymphoma.

The combination of tepotinib plus gefitinib improved progression-free survival and overall response versus chemotherapy in patients with MET mutated EGFR-positive non–small cell lung cancer resistant to prior EGFR TKI therapy.

Eric Smith, MD, PhD, discusses the development of novel CAR T-cell therapies for patients with multiple myeloma.

Frontline therapy may be able to be avoided in asymptomatic, young, fit patients with mantle cell lymphoma.

While clinical trial findings with chimeric antigen receptor (CAR) T-cell therapy have impacted the landscape of pediatric acute lymphoblastic leukemia, additional CAR T-cell products continue to be investigated.

Jonathon B. Cohen, MD, discusses the potential benefit of offering deferred therapy to asymptomatic patients with mantle cell lymphoma.

Talal Hilal, MB, BCh, discusses the findings of a meta-analysis of rituximab maintenance for patients with mantle cell lymphoma (MCL), and the approach to maintenance therapy in patients with MCL.

The CD19-directed chimeric antigen receptor T-cell therapy lisocabtagene maraleucel (JCAR017; liso-cel) is showing promising response rates in patients with high-risk diffuse large B-cell lymphoma.

The CD19-targeted CAR T-cell product axicabtagene ciloleucel (axi-cel; Yescarta) is currently being investigated in patients with relapsed/refractory MCL in the ongoing ZUMA-2 trial.

Anas Younes, MD, discusses the current and future state of CAR T-cell therapies and immune checkpoint inhibitors in the landscape of hematologic malignancies.

Keith Stewart, MB, ChB, discusses the role of stem cell transplant, minimal residual disease testing, and maintenance therapy in the treatment of patients with multiple myeloma.

C. Ola Landgren, MD, PhD, shares his insight on CAR T-cell therapy, sequencing, and triplet and quadruplet regimens in myeloma.

Jae H. Park, MD, discusses the impact of agents such as blinatumomab, inotuzumab ozogamicin, and tisagenlecleucel on the treatment of acute lymphoblastic leukemia.

Sarah B. Goldberg, MD, discusses testing for and treating resistance to EGFR TKI therapy in non-small cell lung cancer.

Jesus Berdeja, MD, discusses ongoing research with bb2121 in patients with relapsed/refractory myeloma.

Babis Andreadis, MD, discusses the successes seen with CAR T-cell development in the past year and the use of CAR T-cell therapy in patients with NHL.

Noelle Frey, MD, discusses the FDA approvals of CAR T-cell therapies, as well as the bright future of the treatment.

Dan T. Vogl, MD, highlights the potential with CAR T-cell therapy in the multiple myeloma paradigm.

Sarah K. Tasian, MD, discusses the success of CAR T-cell therapy, as well as novel agents and immunotherapies that appear promising in the treatment of children with leukemia.

Owen A. O'Connor, MD, PhD, discussed the utilization of acalabrutinib (Calquence), how it sequences with other approved therapies, and the promise for chimeric antigen receptor T-cell therapy in mantle cell lymphoma.

David G. Maloney, MD, PhD, discusses the progress made with CAR T cells, as well as the challenges that still exist in the use of this therapy.

Andre Goy, MD, discusses the recent success with CAR T-cell therapy, and what is on the horizon for this therapeutic option across hematologic malignancies.

Shaji Kumar, MD, discusses his ixazomib maintenance trial, the latest FDA activity in myeloma, and the potential of chimeric antigen receptor (CAR) T-cell therapy in the field of myeloma.

Ezra Cohen, MD, discusses anti–PD-1/PD-L1 combination regimens in HNSCC, the potential for CAR T-cell therapy, and remaining challenges with immunotherapy in the field.

Eric Smith, MD, PhD, discusses the response to CD19 CAR T-cell therapy in B-cell ALL.

Alfred L. Garfall, MD, discusses the latest developments with CAR T-cell therapy in hematologic malignancies

Michel Sadelain, MD, PhD, discusses CRISPR and its effect on CAR T cells.